Viral immune evasion: Lessons in MHC class I antigen presentation

Seminars in Immunology

Volumn 27, Issue 2, 2015, Pages 125-137

  van de Weijer, Michael L ^a   Luteijn, Rutger D ^a   Wiertz, Emmanuel J H J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cross presentation; ERAD; Immune evasion; MHC class I; MHC class II; PLC; TAP; Viral inhibitors

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TAPASIN; HLA ANTIGEN CLASS 1; PEPTIDE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGENICITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CROSS PRESENTATION; ENDOPLASMIC RETICULUM; ENDOSOME; EPSTEIN BARR VIRUS; GENE VECTOR; HUMAN; IMMUNE EVASION; IMMUNE SYSTEM; IMMUNOTHERAPY; NONHUMAN; PHAGOSOME; PROTEIN DEGRADATION; RIBOSOME; RNA TRANSLATION; UBIQUITINATION; UNFOLDED PROTEIN RESPONSE; VIRUS; ANIMAL; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGEN PRESENTATION; ENDOPLASMIC RETICULUM; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE EVASION; PEPTIDES; VIRUSES;

EID: 84931577940     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.03.010     Document Type: Review

References (184)

1. Sadasivan B., Lehner P.J., Ortmann B., Spies T., Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 1996, 5:103-114.
2. Burgert H.G., Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 1985, 41:987-997.
3. Cox J.H., Yewdell J.W., Eisenlohr L.C., Johnson P.R., Bennink J.R. Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science 1990, 247:715-718.
4. Akopian D., Shen K., Zhang X., Shan S. Signal recognition particle: an essential protein-targeting machine. Annu. Rev. Biochem. 2013, 82:693-721. 10.1146/annurev-biochem-072711-164732.
5. Powers C.J., Früh K. Signal peptide-dependent inhibition of MHC class I heavy chain translation by rhesus cytomegalovirus. PLoS Pathog. 2008, 4:e1000150. 10.1371/journal.ppat.1000150.
6. Richards R., Scholz I., Powers C., Skach W.R., Früh K. The cytoplasmic domain of rhesus cytomegalovirus Rh178 interrupts translation of major histocompatibility class I leader peptide-containing proteins prior to translocation. J. Virol. 2011, 85:8766-8776. 10.1128/JVI.05021-11.
7. Rock K.L., Goldberg A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 1999, 17:739-779. 10.1146/annurev.immunol.17.1.739.
8. Leight E.R., Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev. Med. Virol. 2000, 10:83-100.
9. + T cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 2000, 165:7078-7087.
10. Levitskaya J., Coram M., Levitsky V., Imreh S., Steigerwald-Mullen P.M., Klein G., et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995, 375:685-688. 10.1038/375685a0.
11. Levitskaya J., Sharipo A., Leonchiks A., Ciechanover A., Masucci M.G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:12616-12621.
12. Sharipo A., Imreh M., Leonchiks A., Imreh S., Masucci M.G. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 1998, 4:939-944.
13. Daskalogianni C., Apcher S., Candeias M.M., Naski N., Calvo F., Fåhraeus R. Gly-Ala repeats induce position- and substrate-specific regulation of 26 S proteasome-dependent partial processing. J. Biol. Chem. 2008, 283:30090-30100. 10.1074/jbc.M803290200.
14. Lee S.P., Brooks J.M., Al-Jarrah H., Thomas W.A., Haigh T.A., Taylor G.S., et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J. Exp. Med. 2004, 199:1409-1420. 10.1084/jem.20040121.
15. + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J. Exp. Med. 2004, 199:1421-1431. 10.1084/jem.20040191.
16. + T lymphocytes. J. Exp. Med. 2004, 199:459-470. 10.1084/jem.20031219.
17. Ballestas M.E., Chatis P.A., Kaye K.M. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 1999, 284:641-644.
18. Zaldumbide A., Ossevoort M., Wiertz E.J.H.J., Hoeben R.C. In cis inhibition of antigen processing by the latency-associated nuclear antigen I of Kaposi sarcoma herpes virus. Mol. Immunol. 2007, 44:1352-1360. 10.1016/j.molimm.2006.05.012.
19. Kwun H.J., da Silva S.R., Shah I.M., Blake N., Moore P.S., Chang Y. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing. J. Virol. 2007, 81:8225-8235. 10.1128/JVI.00411-07.
20. Heessen S., Leonchiks A., Issaeva N., Sharipo A., Selivanova G., Masucci M.G., et al. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1532-1537. 10.1073/pnas.022306499.
21. Alba R., Bosch A., Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther. 2005, 12(Suppl. 1):S18-S27. 10.1038/sj.gt.3302612.
22. Eggers R., Hendriks W.T.J., Tannemaat M.R., van Heerikhuize J.J., Pool C.W., Carlstedt T.P., et al. Neuroregenerative effects of lentiviral vector-mediated GDNF expression in reimplanted ventral roots. Mol. Cell. Neurosci. 2008, 39:105-117. 10.1016/j.mcn.2008.05.018.
23. Hendriks W.T.J., Eggers R., Carlstedt T.P., Zaldumbide A., Tannemaat M.R., Fallaux F.J., et al. Lentiviral vector-mediated reporter gene expression in avulsed spinal ventral root is short-term, but is prolonged using an immune stealth transgene. Restor. Neurol. Neurosci. 2007, 25:585-599.
24. Hoyng S.A., Gnavi S., de Winter F., Eggers R., Ozawa T., Zaldumbide A., et al. Developing a potentially immunologically inert tetracycline-regulatable viral vector for gene therapy in the peripheral nerve. Gene Ther. 2014, 21:549-557. 10.1038/gt.2014.22.
25. Ossevoort M., Visser B.M.J., van den Wollenberg D.J.M., van der Voort E.I.H., Offringa R., Melief C.J.M., et al. Creation of immune stealth genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1. Gene Ther. 2003, 10:2020-2028. 10.1038/sj.gt.3302098.
26. Zaldumbide A., Weening S., Cramer S.J., Rabelink M.J.W.E., Verhaagen J., Hoeben R.C. A potentially immunologically inert derivative of the reverse tetracycline-controlled transactivator. Biotechnol. Lett. 2010, 32:749-754. 10.1007/s10529-010-0218-8.
27. Vos J.C., Spee P., Momburg F., Neefjes J. Membrane topology and dimerization of the two subunits of the transporter associated with antigen processing reveal a three-domain structure. J. Immunol. 1999, 163:6679-6685.
28. Vos J.C., Reits E.A., Wojcik-Jacobs E., Neefjes J. Head-head/tail-tail relative orientation of the pore-forming domains of the heterodimeric ABC transporter TAP. Curr. Biol. 2000, 10:1-7.
29. Parcej D., Tampé R. ABC proteins in antigen translocation and viral inhibition. Nat. Chem. Biol. 2010, 6:572-580. 10.1038/nchembio.410.
30. Attaya M., Jameson S., Martinez C.K., Hermel E., Aldrich C., Forman J., et al. Ham-2 corrects the class I antigen-processing defect in RMA-S cells. Nature 1992, 355:647-649. 10.1038/355647a0.
31. Spies T., DeMars R. Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature 1991, 351:323-324. 10.1038/351323a0.
32. Franksson L., Petersson M., Kiessling R., Kärre K. Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. Eur. J. Immunol. 1993, 23:2606-2613. 10.1002/eji.1830231034.
33. Ohlén C., Bastin J., Ljunggren H.G., Foster L., Wolpert E., Klein G., et al. Resistance to H-2-restricted but not to allo-H2-specific graft and cytotoxic T lymphocyte responses in lymphoma mutant. J. Immunol. 1990, 145:52-58.
34. Alzhanova D., Edwards D.M., Hammarlund E., Scholz I.G., Horst D., Wagner M.J., et al. Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition. Cell Host Microbe 2009, 6:433-445. 10.1016/j.chom.2009.09.013.
35. Byun M., Verweij M.C., Pickup D.J., Wiertz E.J.H.J., Hansen T.H., Yokoyama W.M. Two mechanistically distinct immune evasion proteins of cowpox virus combine to avoid antiviral CD8 T cells. Cell Host Microbe 2009, 6:422-432. 10.1016/j.chom.2009.09.012.
36. Luteijn R.D., Hoelen H., Kruse E., van Leeuwen W.F., Grootens J., Horst D., et al. Cowpox virus protein CPXV012 eludes CTLs by blocking ATP binding to TAP. J. Immunol. 2014, 193:1578-1589. 10.4049/jimmunol.1400964.
37. Lin J., Eggensperger S., Hank S., Wycisk A.I., Wieneke R., Mayerhofer P.U., et al. A negative feedback modulator of antigen processing evolved from a frame shift in the cowpox virus genome. PLoS Pathog. 2014, 10:e1004554. 10.1371/journal.ppat.1004554.
38. Fruh K., Ahn K., Djaballah H., Sempe P., van Endert P.M., Tampe R., et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995, 375:415-418. 10.1038/375415a0.
39. Hill A., Jugovic P., York I., Russ G., Bennink J., Yewdell J., et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995, 375:411-415. 10.1038/375411a0.
40. Tomazin R., Hill A.B., Jugovic P., York I., van Endert P., Ploegh H.L., et al. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J. 1996, 15:3256-3266.
41. Ahn K., Meyer T.H., Uebel S., Sempé P., Djaballah H., Yang Y., et al. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. 1996, 15:3247-3255.
42. Gorbulev S., Abele R., Tampé R. Allosteric crosstalk between peptide-binding, transport, and ATP hydrolysis of the ABC transporter TAP. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:3732-3737. 10.1073/pnas.061467898.
43. Ahn K., Gruhler A., Galocha B., Jones T.R., Wiertz E.J., Ploegh H.L., et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 1997, 6:613-621.
44. Hengel H., Koopmann J.O., Flohr T., Muranyi W., Goulmy E., Hämmerling G.J., et al. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 1997, 6:623-632.
45. Lehner P.J., Karttunen J.T., Wilkinson G.W., Cresswell P. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:6904-6909.
46. Hewitt E.W., Gupta S.S., Lehner P.J. The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. EMBO J. 2001, 20:387-396. 10.1093/emboj/20.3.387.
47. Reits E.A., Vos J.C., Grommé M., Neefjes J. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature 2000, 404:774-778. 10.1038/35008103.
48. Koppers-Lalic D., Reits E.A.J., Ressing M.E., Lipinska A.D., Abele R., Koch J., et al. Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5144-5149. 10.1073/pnas.0501463102.
49. Koppers-Lalic D., Verweij M.C., Lipińska A.D., Wang Y., Quinten E., Reits E.A., et al. Varicellovirus UL 49.5 proteins differentially affect the function of the transporter associated with antigen processing, TAP. PLoS Pathog. 2008, 4:e1000080. 10.1371/journal.ppat.1000080.
50. Verweij M.C., Lipinska A.D., Koppers-Lalic D., van Leeuwen W.F., Cohen J.I., Kinchington P.R., et al. The capacity of UL49.5 proteins to inhibit TAP is widely distributed among members of the genus Varicellovirus. J. Virol. 2011, 85:2351-2363. 10.1128/JVI.01621-10.
51. + T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J. Exp. Med. 2007, 204:1863-1873. 10.1084/jem.20070256.
52. Horst D., Favaloro V., Vilardi F., van Leeuwen H.C., Garstka M.A., Hislop A.D., et al. EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP. J. Immunol. 2011, 186:3594-3605. 10.4049/jimmunol.1002656.
53. Wycisk A.I., Lin J., Loch S., Hobohm K., Funke J., Wieneke R., et al. Epstein-Barr viral BNLF2a protein hijacks the tail-anchored protein insertion machinery to block antigen processing by the transport complex TAP. J. Biol. Chem. 2011, 286:41402-41412.
54. Koch J., Guntrum R., Heintke S., Kyritsis C., Tampé R. Functional dissection of the transmembrane domains of the transporter associated with antigen processing (TAP). J. Biol. Chem. 2004, 279:10142-10147. 10.1074/jbc.M312816200.
55. Bangia N., Lehner P.J., Hughes E.A., Surman M., Cresswell P. The N-terminal region of tapasin is required to stabilize the MHC class I loading complex. Eur. J. Immunol. 1999, 29:1858-1870. 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C.
56. Lehner P.J., Surman M.J., Cresswell P. Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line.220. Immunity 1998, 8:221-231.
57. Ortmann B., Copeman J., Lehner P.J., Sadasivan B., Herberg J.A., Grandea A.G., et al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 1997, 277:1306-1309.
58. Van der Burg S.H., Visseren M.J., Brandt R.M., Kast W.M., Melief C.J. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 1996, 156:3308-3314.
59. Barnden M.J., Purcell A.W., Gorman J.J., McCluskey J. Tapasin-mediated retention and optimization of peptide ligands during the assembly of class I molecules. J. Immunol. 2000, 165:322-330.
60. Wearsch P.A., Cresswell P. Selective loading of high-affinity peptides onto major histocompatibility complex class I molecules by the tapasin-ERp57 heterodimer. Nat. Immunol. 2007, 8:873-881. 10.1038/ni1485.
61. Park B., Lee S., Kim E., Ahn K. A single polymorphic residue within the peptide-binding cleft of MHC class I molecules determines spectrum of tapasin dependence. J. Immunol. 2003, 170:961-968.
62. Beissbarth T., Sun J., Kavathas P.B., Ortmann B. Increased efficiency of folding and peptide loading of mutant MHC class I molecules. Eur. J. Immunol. 2000, 30:1203-1213. 10.1002/(SICI)1521-4141(200004)30:4<1203::AID-IMMU1203>3.0.CO;2-L.
63. Turnquist H.R., Thomas H.J., Prilliman K.R., Lutz C.T., Hildebrand W.H., Solheim J.C. HLA-B polymorphism affects interactions with multiple endoplasmic reticulum proteins. Eur. J. Immunol. 2000, 30:3021-3028. 10.1002/1521-4141(200010)30:10<3021::AID-IMMU3021>3.0.CO;2-U.
64. Williams A.P., Peh C.A., Purcell A.W., McCluskey J., Elliott T. Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity 2002, 16:509-520.
65. Grandea A.G., Golovina T.N., Hamilton S.E., Sriram V., Spies T., Brutkiewicz R.R., et al. Impaired assembly yet normal trafficking of MHC class I molecules in Tapasin mutant mice. Immunity 2000, 13:213-222.
66. Park B., Kim Y., Shin J., Lee S., Cho K., Früh K., et al. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 2004, 20:71-85.
67. Jones T.R., Wiertz E.J., Sun L., Fish K.N., Nelson J.A., Ploegh H.L. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:11327-11333.
68. Cox J.H., Bennink J.R., Yewdell J.W. Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation. J. Exp. Med. 1991, 174:1629-1637.
69. Bennett E.M., Bennink J.R., Yewdell J.W., Brodsky F.M. Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J. Immunol. 1999, 162:5049-5052.
70. Dong G., Wearsch P.A., Peaper D.R., Cresswell P., Reinisch K.M. Insights into MHC class I peptide loading from the structure of the tapasin-ERp57 thiol oxidoreductase heterodimer. Immunity 2009, 30:21-32. 10.1016/j.immuni.2008.10.018.
71. Agrawal S., Reemtsma K., Bagiella E., Oluwole S.F., Braunstein N.S. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell. Immunol. 2004, 228:130-137. 10.1016/j.cellimm.2004.04.006.
72. Cromme F.V., Airey J., Heemels M.T., Ploegh H.L., Keating P.J., Stern P.L., et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 1994, 179:335-340.
73. Kasajima A., Sers C., Sasano H., Jöhrens K., Stenzinger A., Noske A., et al. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum. Pathol. 2010, 41:1758-1769. 10.1016/j.humpath.2010.05.014.
74. Restifo N.P., Esquivel F., Kawakami Y., Yewdell J.W., Mulé J.J., Rosenberg S.A., et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 1993, 177:265-272.
75. Seliger B., Hohne A., Knuth A., Bernhard H., Meyer T., Tampe R., et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res. 1996, 56:1756-1760.
76. Henderson R.A., Michel H., Sakaguchi K., Shabanowitz J., Appella E., Hunt D.F., et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992, 255:1264-1266.
77. Wei M.L., Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 1992, 356:443-446. 10.1038/356443a0.
78. Van Hall T., Wolpert E.Z., van Veelen P., Laban S., van der Veer M., Roseboom M., et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat. Med. 2006, 12:417-424. 10.1038/nm1381.
79. + T cells specific for transporter associated with antigen processing deficient cells. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:11496-11501.
80. Chambers B., Grufman P., Fredriksson V., Andersson K., Roseboom M., Laban S., et al. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination. Cancer Res. 2007, 67:8450-8455. 10.1158/0008-5472.CAN-07-1092.
81. Van Hall T., Laban S., Koppers-Lalic D., Koch J., Precup C., Asmawidjaja P., et al. The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1. J. Immunol. 2007, 178:657-662.
82. + T cell responses against TAP-inhibited cells are readily detected in the human population. J. Immunol. 2010, 185:6508-6517. 10.4049/jimmunol.1001774.
83. Guéguen M., Biddison W.E., Long E.O. T cell recognition of an HLA-A2-restricted epitope derived from a cleaved signal sequence. J. Exp. Med. 1994, 180:1989-1994.
84. Thammavongsa V., Raghuraman G., Filzen T.M., Collins K.L., Raghavan M. HLA-B44 polymorphisms at position 116 of the heavy chain influence TAP complex binding via an effect on peptide occupancy. J. Immunol. 2006, 177:3150-3161.
85. Zernich D., Purcell A.W., Macdonald W.A., Kjer-Nielsen L., Ely L.K., Laham N., et al. Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion. J. Exp. Med. 2004, 200:13-24. 10.1084/jem.20031680.
86. Hughes E.A., Hammond C., Cresswell P. Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:1896-1901.
87. Wiertz E.J., Tortorella D., Bogyo M., Yu J., Mothes W., Jones T.R., et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 1996, 384:432-438. 10.1038/384432a0.
88. Wiertz E.J., Jones T.R., Sun L., Bogyo M., Geuze H.J., Ploegh H.L. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996, 84:769-779.
89. Lilley B.N., Tortorella D., Ploegh H.L. Dislocation of a type I membrane protein requires interactions between membrane-spanning segments within the lipid bilayer. Mol. Biol. Cell 2003, 14:3690-3698. 10.1091/mbc.E03-03-0192.
90. Ye Y., Shibata Y., Yun C., Ron D., Rapoport T.A. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature 2004, 429:841-847. 10.1038/nature02656.
91. Lilley B.N., Ploegh H.L. A membrane protein required for dislocation of misfolded proteins from the ER. Nature 2004, 429:834-840. 10.1038/nature02592.
92. Cho S., Lee M., Jun Y. Forced interaction of cell surface proteins with Derlin-1 in the endoplasmic reticulum is sufficient to induce their dislocation into the cytosol for degradation. Biochem. Biophys. Res. Commun. 2013, 430:787-792. 10.1016/j.bbrc.2012.11.068.
93. Van de Weijer M.L., Bassik M.C., Luteijn R.D., Voorburg C.M., Lohuis M.A.M., Kremmer E., et al. A high-coverage shRNA screen identifies TMEM129 as an E3 ligase involved in ER-associated protein degradation. Nat. Commun. 2014, 5:3832. 10.1038/ncomms4832.
94. Van den Boomen D.J.H., Timms R.T., Grice G.L., Stagg H.R., Skødt K., Dougan G., et al. TMEM129 is a Derlin-1 associated ERAD E3 ligase essential for virus-induced degradation of MHC-I. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:11425-11430. 10.1073/pnas.1409099111.
95. Ye Y., Meyer H.H., Rapoport T.A. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature 2001, 414:652-656. 10.1038/414652a.
96. Flierman D., Coleman C.S., Pickart C.M., Rapoport T.A., Chau V. E2-25K mediates US11-triggered retro-translocation of MHC class I heavy chains in a permeabilized cell system. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11589-11594. 10.1073/pnas.0605215103.
97. Hirsch C., Blom D., Ploegh H.L. A role for N-glycanase in the cytosolic turnover of glycoproteins. EMBO J. 2003, 22:1036-1046. 10.1093/emboj/cdg107.
98. Loureiro J., Lilley B.N., Spooner E., Noriega V., Tortorella D., Ploegh H.L. Signal peptide peptidase is required for dislocation from the endoplasmic reticulum. Nature 2006, 441:894-897. 10.1038/nature04830.
99. Stagg H.R., Thomas M., van den Boomen D., Wiertz E.J.H.J., Drabkin H.A., Gemmill R.M., et al. The TRC8 E3 ligase ubiquitinates MHC class I molecules before dislocation from the ER. J. Cell Biol. 2009, 186:685-692. 10.1083/jcb.200906110.
100. Boname J.M., Bloor S., Wandel M.P., Nathan J.A., Antrobus R., Dingwell K.S., et al. Cleavage by signal peptide peptidase is required for the degradation of selected tail-anchored proteins. J. Cell Biol. 2014, 205:847-862. 10.1083/jcb.201312009.
101. Chen C.-Y., Malchus N.S., Hehn B., Stelzer W., Avci D., Langosch D., et al. Signal peptide peptidase functions in ERAD to cleave the unfolded protein response regulator XBP1u. EMBO J. 2014, 10.15252/embj.201488208.
102. Stevenson P.G., Efstathiou S., Doherty P.C., Lehner P.J. Inhibition of MHC class I-restricted antigen presentation by gamma 2-herpesviruses. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8455-8460. 10.1073/pnas.150240097.
103. Boname J.M., Stevenson P.G. MHC class I ubiquitination by a viral PHD/LAP finger protein. Immunity 2001, 15:627-636.
104. Lybarger L., Wang X., Harris M.R., Virgin H.W., Hansen T.H. Virus subversion of the MHC class I peptide-loading complex. Immunity 2003, 18:121-130.
105. Wang X., Herr R.A., Chua W.-J., Lybarger L., Wiertz E.J.H.J., Hansen T.H. Ubiquitination of serine, threonine, or lysine residues on the cytoplasmic tail can induce ERAD of MHC-I by viral E3 ligase mK3. J. Cell Biol. 2007, 177:613-624. 10.1083/jcb.200611063.
106. Wang X., Herr R.A., Rabelink M., Hoeben R.C., Wiertz E.J.H.J., Hansen T.H. Ube2j2 ubiquitinates hydroxylated amino acids on ER-associated degradation substrates. J. Cell Biol. 2009, 187:655-668. 10.1083/jcb.200908036.
107. Herr R.A., Harris J., Fang S., Wang X., Hansen T.H. Role of the RING-CH domain of viral ligase mK3 in ubiquitination of non-lysine and lysine MHC I residues. Traffic 2009, 10:1301-1317. 10.1111/j.1600-0854.2009.00946.x.
108. Wang X., Ye Y., Lencer W., Hansen T.H. The viral E3 ubiquitin ligase mK3 uses the Derlin/p97 endoplasmic reticulum-associated degradation pathway to mediate down-regulation of major histocompatibility complex class I proteins. J. Biol. Chem. 2006, 281:8636-8644. 10.1074/jbc.M513920200.
109. Burr M.L., Cano F., Svobodova S., Boyle L.H., Boname J.M., Lehner P.J. HRD1 and UBE2J1 target misfolded MHC class I heavy chains for endoplasmic reticulum-associated degradation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:2034-2039. 10.1073/pnas.1016229108.
110. Shamu C.E., Flierman D., Ploegh H.L., Rapoport T.A., Chau V. Polyubiquitination is required for US11-dependent movement of MHC class I heavy chain from endoplasmic reticulum into cytosol. Mol. Biol. Cell 2001, 12:2546-2555.
111. Flierman D., Ye Y., Dai M., Chau V., Rapoport T.A. Polyubiquitin serves as a recognition signal, rather than a ratcheting molecule, during retrotranslocation of proteins across the endoplasmic reticulum membrane. J. Biol. Chem. 2003, 278:34774-34782. 10.1074/jbc.M303360200.
112. Cadwell K., Coscoy L. Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science 2005, 309:127-130. 10.1126/science.1110340.
113. Burr M.L., van den Boomen D.J.H., Bye H., Antrobus R., Wiertz E.J., Lehner P.J. MHC class I molecules are preferentially ubiquitinated on endoplasmic reticulum luminal residues during HRD1 ubiquitin E3 ligase-mediated dislocation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:14290-14295. 10.1073/pnas.1303380110.
114. Byun M., Wang X., Pak M., Hansen T.H., Yokoyama W.M. Cowpox virus exploits the endoplasmic reticulum retention pathway to inhibit MHC class I transport to the cell surface. Cell Host Microbe 2007, 2:306-315. 10.1016/j.chom.2007.09.002.
115. McCoy W.H., Wang X., Yokoyama W.M., Hansen T.H., Fremont D.H. Structural mechanism of ER retrieval of MHC class I by cowpox. PLoS Biol. 2012, 10:e1001432. 10.1371/journal.pbio.1001432.
116. Munro S., Pelham H.R. A C-terminal signal prevents secretion of luminal ER proteins. Cell 1987, 48:899-907.
117. Pelham H.R. Evidence that luminal ER proteins are sorted from secreted proteins in a post-ER compartment. EMBO J. 1988, 7:913-918.
118. Andres D.A., Dickerson I.M., Dixon J.E. Variants of the carboxyl-terminal KDEL sequence direct intracellular retention. J. Biol. Chem. 1990, 265:5952-5955.
119. Howe C., Garstka M., Al-Balushi M., Ghanem E., Antoniou A.N., Fritzsche S., et al. Calreticulin-dependent recycling in the early secretory pathway mediates optimal peptide loading of MHC class I molecules. EMBO J. 2009, 28:3730-3744. 10.1038/emboj.2009.296.
120. Coscoy L., Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8051-8056. 10.1073/pnas.140129797.
121. Ishido S., Wang C., Lee B.S., Cohen G.B., Jung J.U. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J. Virol. 2000, 74:5300-5309.
122. Lang S.M., Bynoe M.O.F., Karki R., Tartell M.A., Means R.E. Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins down regulate both DC-SIGN and DC-SIGNR. PLOS ONE 2013, 8:e58056. 10.1371/journal.pone.0058056.
123. Sanchez D.J., Gumperz J.E., Ganem D. Regulation of CD1d expression and function by a herpesvirus infection. J. Clin. Invest. 2005, 115:1369-1378. 10.1172/JCI24041.
124. Rhodes D.A., Boyle L.H., Boname J.M., Lehner P.J., Trowsdale J. Ubiquitination of lysine-331 by Kaposi's sarcoma-associated herpesvirus protein K5 targets HFE for lysosomal degradation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:16240-16245. 10.1073/pnas.1003421107.
125. Li Q., Means R., Lang S., Jung J.U. Downregulation of gamma interferon receptor 1 by Kaposi's sarcoma-associated herpesvirus K3 and K5. J. Virol. 2007, 81:2117-2127. 10.1128/JVI.01961-06.
126. Ishido S., Choi J.K., Lee B.S., Wang C., DeMaria M., Johnson R.P., et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 2000, 13:365-374.
127. Coscoy L., Ganem D. A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J. Clin. Invest. 2001, 107:1599-1606. 10.1172/JCI12432.
128. Bartee E., McCormack A., Früh K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2006, 2:e107. 10.1371/journal.ppat.0020107.
129. Mansouri M., Douglas J., Rose P.P., Gouveia K., Thomas G., Means R.E., et al. Kaposi sarcoma herpesvirus K5 removes CD31/PECAM from endothelial cells. Blood 2006, 108:1932-1940. 10.1182/blood-2005-11-4404.
130. Thomas M., Wills M., Lehner P.J. Natural killer cell evasion by an E3 ubiquitin ligase from Kaposi's sarcoma-associated herpesvirus. Biochem. Soc. Trans. 2008, 36:459-463. 10.1042/BST0360459.
131. Hewitt E.W., Duncan L., Mufti D., Baker J., Stevenson P.G., Lehner P.J. Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation. EMBO J. 2002, 21:2418-2429. 10.1093/emboj/21.10.2418.
132. Boname J.M., Thomas M., Stagg H.R., Xu P., Peng J., Lehner P.J. Efficient internalization of MHC I requires lysine-11 and lysine-63 mixed linkage polyubiquitin chains. Traffic 2010, 11:210-220. 10.1111/j.1600-0854.2009.01011.x.
133. Goto E., Yamanaka Y., Ishikawa A., Aoki-Kawasumi M., Mito-Yoshida M., Ohmura-Hoshino M., et al. Contribution of lysine 11-linked ubiquitination to MIR2-mediated major histocompatibility complex class I internalization. J. Biol. Chem. 2010, 285:35311-35319. 10.1074/jbc.M110.112763.
134. Cadwell K., Coscoy L. The specificities of Kaposi's sarcoma-associated herpesvirus-encoded E3 ubiquitin ligases are determined by the positions of lysine or cysteine residues within the intracytoplasmic domains of their targets. J. Virol. 2008, 82:4184-4189. 10.1128/JVI.02264-07.
135. Dodd R.B., Allen M.D., Brown S.E., Sanderson C.M., Duncan L.M., Lehner P.J., et al. Solution structure of the Kaposi's sarcoma-associated herpesvirus K3 N-terminal domain reveals a Novel E2-binding C4HC3-type RING domain. J. Biol. Chem. 2004, 279:53840-53847. 10.1074/jbc.M409662200.
136. Hofmann R.M., Pickart C.M. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell 1999, 96:645-653.
137. Duncan L.M., Piper S., Dodd R.B., Saville M.K., Sanderson C.M., Luzio J.P., et al. Lysine-63-linked ubiquitination is required for endolysosomal degradation of class I molecules. EMBO J. 2006, 25:1635-1645. 10.1038/sj.emboj.7601056.
138. Ye Y., Rape M. Building ubiquitin chains: E2 enzymes at work. Nat. Rev. Mol. Cell Biol. 2009, 10:755-764. 10.1038/nrm2780.
139. Goto E., Ishido S., Sato Y., Ohgimoto S., Ohgimoto K., Nagano-Fujii M., et al. c-MIR, a human E3 ubiquitin ligase, is a functional homolog of herpesvirus proteins MIR1 and MIR2 and has similar activity. J. Biol. Chem. 2003, 278:14657-14668. 10.1074/jbc.M211285200.
140. Bartee E., Mansouri M., Hovey Nerenberg B.T., Gouveia K., Früh K. Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins. J. Virol. 2004, 78:1109-1120.
141. Matsuki Y., Ohmura-Hoshino M., Goto E., Aoki M., Mito-Yoshida M., Uematsu M., et al. Novel regulation of MHC class II function in B cells. EMBO J. 2007, 26:846-854. 10.1038/sj.emboj.7601556.
142. Ohmura-Hoshino M., Matsuki Y., Aoki M., Goto E., Mito M., Uematsu M., et al. Inhibition of MHC class II expression and immune responses by c-MIR. J. Immunol. 2006, 177:341-354.
143. De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N., Pierre P., et al. MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3491-3496. 10.1073/pnas.0708874105.
144. Furuta K., Walseng E., Roche P.A. Internalizing MHC class II-peptide complexes are ubiquitinated in early endosomes and targeted for lysosomal degradation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:20188-20193. 10.1073/pnas.1312994110.
145. Eyster C.A., Cole N.B., Petersen S., Viswanathan K., Früh K., Donaldson J.G. MARCH ubiquitin ligases alter the itinerary of clathrin-independent cargo from recycling to degradation. Mol. Biol. Cell 2011, 22:3218-3230. 10.1091/mbc.E10-11-0874.
146. Walseng E., Furuta K., Bosch B., Weih K.A., Matsuki Y., Bakke O., et al. Ubiquitination regulates MHC class II-peptide complex retention and degradation in dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:20465-20470. 10.1073/pnas.1010990107.
147. Van Niel G., Wubbolts R., Ten Broeke T., Buschow S.I., Ossendorp F.A., Melief C.J., et al. Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitination. Immunity 2006, 25:885-894. 10.1016/j.immuni.2006.11.001.
148. Shin J.-S., Ebersold M., Pypaert M., Delamarre L., Hartley A., Mellman I. Surface expression of MHC class II in dendritic cells is controlled by regulated ubiquitination. Nature 2006, 444:115-118. 10.1038/nature05261.
149. Tze L.E., Horikawa K., Domaschenz H., Howard D.R., Roots C.M., Rigby R.J., et al. CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation. J. Exp. Med. 2011, 208:149-165. 10.1084/jem.20092203.
150. Ma J.K., Platt M.Y., Eastham-Anderson J., Shin J.-S., Mellman I. MHC class II distribution in dendritic cells and B cells is determined by ubiquitin chain length. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:8820-8827. 10.1073/pnas.1202977109.
151. Burgdorf S., Schölz C., Kautz A., Tampé R., Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol. 2008, 9:558-566. 10.1038/ni.1601.
152. Ackerman A.L., Kyritsis C., Tampé R., Cresswell P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12889-12894. 10.1073/pnas.1735556100.
153. Houde M., Bertholet S., Gagnon E., Brunet S., Goyette G., Laplante A., et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003, 425:402-406. 10.1038/nature01912.
154. Guermonprez P., Saveanu L., Kleijmeer M., Davoust J., Van Endert P., Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003, 425:397-402. 10.1038/nature01911.
155. Ackerman A.L., Giodini A., Cresswell P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 2006, 25:607-617. 10.1016/j.immuni.2006.08.017.
156. Touret N., Paroutis P., Terebiznik M., Harrison R.E., Trombetta S., Pypaert M., et al. Quantitative and dynamic assessment of the contribution of the ER to phagosome formation. Cell 2005, 123:157-170. 10.1016/j.cell.2005.08.018.
157. Lencer W.I., Tsai B. The intracellular voyage of cholera toxin: going retro. Trends Biochem. Sci. 2003, 28:639-645. 10.1016/j.tibs.2003.10.002.
158. Lord J.M., Spooner R.A. Ricin trafficking in plant and mammalian cells. Toxins (Basel) 2011, 3:787-801. 10.3390/toxins3070787.
159. Ackerman A.L., Kyritsis C., Tampé R., Cresswell P. Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat. Immunol. 2005, 6:107-113. 10.1038/ni1147.
160. Koopmann J.O., Albring J., Hüter E., Bulbuc N., Spee P., Neefjes J., et al. Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity 2000, 13:117-127.
161. Ménager J., Ebstein F., Oger R., Hulin P., Nedellec S., Duverger E., et al. Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1. PLOS ONE 2014, 9:e89897. 10.1371/journal.pone.0089897.
162. Kaufmann S.H., Schaible U.E. Antigen presentation and recognition in bacterial infections. Curr. Opin. Immunol. 2005, 17:79-87. 10.1016/j.coi.2004.12.004.
163. Bomberger J.M., Ely K.H., Bangia N., Ye S., Green K.A., Green W.R., et al. Pseudomonas aeruginosa Cif protein enhances the ubiquitination and proteasomal degradation of the transporter associated with antigen processing (TAP) and reduces major histocompatibility complex (MHC) class I antigen presentation. J. Biol. Chem. 2014, 289:152-162. 10.1074/jbc.M113.459271.
164. Albaghdadi H., Robinson N., Finlay B., Krishnan L., Sad S. Selectively reduced intracellular proliferation of Salmonella enterica serovar typhimurium within APCs limits antigen presentation and development of a rapid CD8 T cell response. J. Immunol. 2009, 183:3778-3787. 10.4049/jimmunol.0900843.
165. + T cell epitope repertoire of host cytosol-exposed proteins to manipulate the host immune response. PLoS Comput. Biol. 2011, 7:e1002220. 10.1371/journal.pcbi.1002220.
166. Smiley J.R. Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase?. J. Virol. 2004, 78:1063-1068.
167. Abendroth A., Lin I., Slobedman B., Ploegh H., Arvin A.M. Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J. Virol. 2001, 75:4878-4888. 10.1128/JVI.75.10.4878-4888.2001.
168. Eisfeld A.J., Yee M.B., Erazo A., Abendroth A., Kinchington P.R. Downregulation of class I major histocompatibility complex surface expression by varicella-zoster virus involves open reading frame 66 protein kinase-dependent and -independent mechanisms. J. Virol. 2007, 81:9034-9049. 10.1128/JVI.00711-07.
169. + T cells through an additional host shutoff function. J. Virol. 2008, 82:2385-2393. 10.1128/JVI.01946-07.
170. Rowe M., Glaunsinger B., van Leeuwen D., Zuo J., Sweetman D., Ganem D., et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3366-3371. 10.1073/pnas.0611128104.
171. Zuo J., Currin A., Griffin B.D., Shannon-Lowe C., Thomas W.A., Ressing M.E., et al. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 2009, 5:e1000255. 10.1371/journal.ppat.1000255.
172. Park B., Spooner E., Houser B.L., Strominger J.L., Ploegh H.L. The HCMV membrane glycoprotein US10 selectively targets HLA-G for degradation. J. Exp. Med. 2010, 207:2033-2041. 10.1084/jem.20091793.
173. Kleijnen M.F., Huppa J.B., Lucin P., Mukherjee S., Farrell H., Campbell A.E., et al. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J. 1997, 16:685-694. 10.1093/emboj/16.4.685.
174. Babić M., Pyzik M., Zafirova B., Mitrović M., Butorac V., Lanier L.L., et al. Cytomegalovirus immunoevasin reveals the physiological role of missing self recognition in natural killer cell dependent virus control in vivo. J. Exp. Med. 2010, 207:2663-2673. 10.1084/jem.20100921.
175. Reusch U., Muranyi W., Lucin P., Burgert H.G., Hengel H., Koszinowski U.H. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J. 1999, 18:1081-1091. 10.1093/emboj/18.4.1081.
176. Khan S., Zimmermann A., Basler M., Groettrup M., Hengel H. A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J. Virol. 2004, 78:1831-1842.
177. Ziegler H., Thale R., Lucin P., Muranyi W., Flohr T., Hengel H., et al. A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity 1997, 6:57-66.
178. Hudson A.W., Howley P.M., Ploegh H.L. A human herpesvirus 7 glycoprotein, U21, diverts major histocompatibility complex class I molecules to lysosomes. J. Virol. 2001, 75:12347-12358. 10.1128/JVI.75.24.12347-12358.2001.
179. Hudson A.W., Blom D., Howley P.M., Ploegh H.L. The ER-lumenal domain of the HHV-7 immunoevasin U21 directs class I MHC molecules to lysosomes. Traffic 2003, 4:824-837.
180. Glosson N.L., Hudson A.W. Human herpesvirus-6A and -6B encode viral immunoevasins that downregulate class I MHC molecules. Virology 2007, 365:125-135. 10.1016/j.virol.2007.03.048.
181. Glosson N.L., Gonyo P., May N.A., Schneider C.L., Ristow L.C., Wang Q., et al. Insight into the mechanism of human herpesvirus 7 U21-mediated diversion of class I MHC molecules to lysosomes. J. Biol. Chem. 2010, 285:37016-37029. 10.1074/jbc.M110.125849.
182. May N.A., Glosson N.L., Hudson A.W. Human herpesvirus 7 u21 downregulates classical and nonclassical class I major histocompatibility complex molecules from the cell surface. J. Virol. 2010, 84:3738-3751. 10.1128/JVI.01782-09.
183. Glaunsinger B., Ganem D. Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover. Mol. Cell 2004, 13:713-723.
184. Glaunsinger B., Chavez L., Ganem D. The exonuclease and host shutoff functions of the SOX protein of Kaposi's sarcoma-associated herpesvirus are genetically separable. J. Virol. 2005, 79:7396-7401. 10.1128/JVI.79.12.7396-7401.2005.